Yes I agree on the long term CSL will do well with $1B R&D budget. But on the short term with this uncertainty on their revenue, I doubt investors will be paying high PE multiple. CSL will have to demonstrate some visible potential products which are almost ready for the market or Vifor & Vaccine business come up with compensating increase in revenue. I think that is there issue at the moment.
UBS - CSL no need to worry about Argenx, page-7
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.18 |
Change
3.130(1.02%) |
Mkt cap ! $150.7B | |||
| Open | High | Low | Value | Volume |
| $310.00 | $312.47 | $310.00 | $43.26M | 139.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 146 | $311.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.18 | 57 | 7 |
View Market Depth
| Last trade - 12.27pm 29/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |